Medicines development and regulation in Africa

© 2017 by the Author(s). Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Africa is one of the world’s fastest-growing economic regions, with a rise in its pharmaceutical industry value from $4.7 billion in 2003 to $20.8 billion in 2013. Multinational pharmaceutical companies are becoming more active in drug production and clinical trials across Africa, and there is an increase in the number of local companies engaged in medicines development and marketing. Such expansion of the local pharmaceutical industry requires trained pharmaceutical specialists to support it. The current situation and future requirements for local medicines development, regulation, education and training needs are discussed.

Keywords

medicines development

medicines regulation

Africa

training

education

PharmaTrain

IFAPP

SAHPRA

References

1. McKinsey & Company Report, 2015, Insights into pharmaceuticals and medical products in Africa: A continent of opportunity for pharma and patients, viewed July 3, 2015, <www.mckinsey.com/insights/health_systems_and_services/africa_a_continent_of_opportunity_for_pharma_and_patients>
2. World Health Organization Regional Office for Africa, 2014, Disease burden — Non-communicable diseases and conditions, viewed July 3, 2015, <www.aho.afro.who.int/profiles_information/index.php/AFRO:Disease_burden_-_Non-communicable_diseases_and_conditions>
3. Kahn M and Gastrow M, 2008, Pharmacologically active: Clinical trials and the pharmaceutical industry. South Africa Medical Journal, vol. 98(2): 114–116.
4. Strugo V, Katsoulis L, Chikoto H, et al. 2011, Conducting clinical trials in South Africa. In Chin R and Bairu M (eds), Global Clinical Trials (Chapter 13), Academic Press, 245–270. http://dx.doi.org/10.1016/B978-0-12-381537-8.10013-5
5. Isaakidis, P, Swingler, GH, Pienaar, E, et al. 2002, Relation between burden of disease and randomized evidence in sub-Saharan Africa: Survey of research. BMJ, vol.324(7339): 702–706. http://dx.doi.org/10.1136/bmj.324.7339.702
6. Siegfried N, Clarke M and Volmink J, 2005, Randomised controlled trials in Africa of HIV and AIDS: Descriptive study and spatial distribution. BMJ, vol.331(7519): 742–747. http://dx.doi.org/10.1136/bmj.331.7519.742
7. Rago L. Regulatory appraisal of biological medicines and harmonization initiatives for availability and access. 17th World Congress of Basic and Clinical Pharmacology (WCP 2014), Cape Town, South Africa; Biological medicines development (PharfA Symposium 3)
8. Walubo A, Barnes K, Kwizera E, et al. 2013, Clinical Pharmacology becomes a specialty in South Africa. South African Medical Journal vol.103(3): 150–151. http://dx.doi.org/10.7196/SAMJ.6639
9. Fundisa African Academy of Medicines Development, 2015, viewed July 3, 2015, <http://www.fundisa-academy.com/>
10. The Global Health Network, 2015, Global health trials, viewed July 21, 2015, <https://globalhealthtrials.tghn.org/>
11. Kerpel-Fronius S, Rosenkranz B, Allen E, et al. 2015, Education and training for medicines development, regulation and clinical research in emerging countries. Frontiers in Pharmacology, vol.6: 80. http://dx.doi.org/10.3389/fphar.2015.00080

Conflict of interest

No conflict of interest has been reported by the authors.

Previous article in this issue

Next article in this issue